GoldiloxBio

Transforming Drug Discovery with models that reflect human physiology.

Based based in Indianapolis, Indiana, GoldiloxBio works in lifetech.

Profile

GoldiloxBio is an innovative lifetech company focused on transforming drug discovery through the development of advanced assays that accurately predict human toxicities. By integrating hardware, software, and biomaterials, the company recreates critical aspects of human physiology in vitro to provide drug developers with predictive, human-relevant data. This approach addresses the limitations of traditional animal models, offering faster, more cost-effective, and reliable insights that help de-risk drug candidates before clinical trials. GoldiloxBio’s platform aims to accelerate development timelines and improve clinical success rates by delivering actionable information on drug safety. The company’s initial service focuses on cardiotoxicity testing, with ongoing efforts to enhance data interpretation through machine learning. GoldiloxBio’s contributions represent a significant advancement in preclinical testing, supporting innovation in drug development and reducing reliance on less predictive models.

GoldiloxBio is positioned in lifetech, a segment that rewards a clear, focused offering.

The company is recorded as being based in Indianapolis, Indiana.

The company is listed at the Plug and Play accelerated startup stage of development.

Website: www.goldilox.bio